CLCGY:OTC-Clicks Group Limited (USD)

COMMON STOCK | Pharmaceutical Retailers | OTC

Last Closing Price

USD 36.90

Change

0.00 (0.00)%

Market Cap

USD 4.45B

Volume

278.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Clicks Group Limited operates as a health and beauty retailer, and pharmaceutical distributor and wholesaler primarily in South Africa. The company operates in two segments, Retail and Distribution. It retails pharmacy, health and beauty through approximately 740 stores, and 580 in-store pharmacies for the middle to upper income markets under the Clicks name. The company also retails specialty health and wellness products, including vitamins, mineral and herbal supplements, sports nutrition, and slimming products under the General Nutrition Corporation (GNC) name; luxury toiletries, cosmetics, gifting, and grooming products under The Body Shop name; and fashionable jewelry and accessories for young women and girls under the Claire's name. In addition, it retails music and related entertainment merchandise, such as music and movie DVDs; computer games; and technology and accessories comprising headphones portable speakers, phone and tablet covers, docking stations, and tablets under the Musica name. Further, the company is involved in the wholesale and supply of pharmaceutical products to retail pharmacies, private hospitals, dispensing doctors, and retail health stores under the UPD name. The company was formerly known as New Clicks Holdings Limited and changed its name to Clicks Group Limited in June 2009. Clicks Group Limited was founded in 1968 and is based in Cape Town, South Africa.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALBHF Alibaba Health Information Tec..

+0.03 (+1.06%)

USD38.23B 940.00 101.70
RADLY Raia Drogasil S.A

N/A

USD8.01B 87.41 4.44
SDGCF Sundrug Co.,Ltd

N/A

USD4.16B 19.28 0.09
ZRSEF Zur Rose Group AG

N/A

USD3.20B N/A N/A
FFLWF Fire & Flower Holdings Corp

N/A

USD0.28B N/A 11.91
DRVD Driven Deliveries, Inc

N/A

USD0.06B N/A N/A
RXMD Progressive Care, Inc

N/A

USD0.04B N/A 36.97
HEWA HealthWarehouse.com, Inc

N/A

USD0.01B 45.25 N/A
RLLVF Relevium Technologies Inc

N/A

USD4.27M N/A N/A
CNBI China BCT Pharmacy Group, Inc

N/A

USD1.78M 0.13 N/A

ETFs Containing CLCGY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Pharmaceutical Retailers)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.19% 35% F 37% F
Dividend Return 1.77% 67% D+ 54% F
Total Return 7.96% 29% F 39% F
Trailing 12 Months  
Capital Gain 51.42% 59% F 48% F
Dividend Return 2.52% 67% D+ 31% F
Total Return 53.94% 53% F 48% F
Trailing 5 Years  
Capital Gain 178.91% 73% C 75% C
Dividend Return 13.64% 100% A+ 51% F
Total Return 192.55% 73% C 75% C
Average Annual (5 Year Horizon)  
Capital Gain 17.04% 41% F 59% F
Dividend Return 1.32% 67% D+ 35% F
Total Return 18.36% 35% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 26.08% 100% A+ 70% C-
Risk Adjusted Return 70.41% 94% A 91% A-
Market Capitalization 4.45B 88% B+ 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Pharmaceutical Retailers)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.55 57% F 24% F
Price/Book Ratio 14.08 33% F 12% F
Price / Cash Flow Ratio 1.90 38% F 35% F
EV/EBITDA 1.07 71% C- 65% D
Management Effectiveness  
Return on Equity 41.83% 100% A+ 96% A
Return on Invested Capital 40.73% 93% A 89% B+
Return on Assets 11.21% 100% A+ 95% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.04 76% C 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector